Optometrists in Corona, NY Accepting Medicare
25 Optometrists found. Showing 21 - 25
 Dr. Niki Tsamis, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 3781 Junction Blvd, Corona, NY 11368 Phone: 718-424-1333 |
Dr. Tressa Mahmood, OD Optometrist Medicare: Medicare Enrolled Practice Location: 3740 Junction Blvd, Corona, NY 11368 Phone: 718-507-8114 |
 Dr. Austin J. Marolla, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 10219 Roosevelt Ave, Corona, NY 11368 Phone: 646-479-0415 Fax: 718-507-2729 |
Rokhel Kaziyev, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 10306 Roosevelt Ave, Corona, NY 11368 Phone: 718-424-1333 |
 Iea Junction Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3781 Junction Blvd, Corona, NY 11368 Phone: 347-717-6952 |
News Archive
PBS Newshour examines proposed changes to U.S. food aid program
PBS NewsHour on Wednesday aired two video reports examining proposed changes to the U.S. food aid program included in President Obama's FY 2014 budget request released this month.
Congressional heavy-hitters back Michigan's MLR waiver request
Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.
Oral nutriceutical restores vision to otherwise hopeless patients facing permanent loss
There may be new found hope for patients whose vision is threatened when medicine injected directly into the eyes fails to cause abnormal blood vessels to recede. While injectable drugs called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered a modern miracle and have become the standard of care for patients with the fast-progressive form of macular degeneration, they are not foolproof.
Genesis Biopharma closes private offerings to purchase 845,000 shares of common stock
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced that it closed private offerings in December and October 2010 pursuant to which it entered into definitive agreements with accredited investors to purchase a total of 845,000 shares of the Genesis Biopharma common stock for a purchase price of $1.00 per share.
› Verified 3 days ago
- 1
- 2(current)
Speech-Language Pathologists
Physical Therapists
Optometrists
Chiropractors
Occupational Therapists
Podiatrists